CTIC CTI BioPharma Corp.

4.29
+0  (3%)
Previous Close 4.16
Open 4.22
Price To book 8.76
Market Cap 120.31M
Shares 28,045,000
Volume 47,556
Short Ratio 6.43
Av. Daily Volume 281,082

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17688658
  2. 8-K - Current report 17686209
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17659869
  4. 8-K - Current report 17658903
  5. 8-K - Current report 17658818

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
PIXUVRI
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Announced January 5, 2017 removal of clinical hold. Additional trial to commence 2Q 2017.
Pacritinib
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
  2. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  3. CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  4. CTI BIOPHARMA CORP Financials
  5. CTI BioPharma to Present at the 29th Annual ROTH Conference
  6. CTI BioPharma reports 4Q loss
  7. CTI BioPharma reports 4Q loss
  8. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  9. CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
  10. Q4 2016 CTi Biopharma Corp Earnings Release - After Market Close
  11. CTI BioPharma hires new CEO
  12. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  13. CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
  14. CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
  15. CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
  16. CTI BioPharma to Present at the BIO CEO & Investor Conference
  17. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  18. CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  19. CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
  20. CTI BIOPHARMA CORP Files SEC form 8-K, Other Events

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 17688658
  2. 8-K - Current report 17686209
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17659869
  4. 8-K - Current report 17658903
  5. 8-K - Current report 17658818
  6. 8-K - Current report 17642726
  7. 8-K - Current report 17642653
  8. 8-K - Current report 17594452
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17589189
  10. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17588330